Ontario Patients – Please join us for our very first Patient Empowerment Pilot Project Workshop.
The CFA is honoured and proud to share this Rare Disease Hero Video featuring Kaye LeMoine….
In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.
The Board is responsible for the highest level of decision-making and communicates the organization’s vision to all members and the community.
The Annual WORLDSymposium is often cited as the most important scientific meeting on lysosomal molecular biology, disorders and treatment.
The Canadian Organization for Rare Disorders (CORD) is hosting a Rare Disease Day 2017 conference taking place on March 30-31, 2017.
The fifth Fabry International Expert Meeting is taking place on May 19 & 20, 2017 at the Royal Olympic Hotel in Athens, Greece.
Rare Disease Day takes place on the last day of February each year. Stay tuned for what YOU can do as a Canadian Fabry patient on this day.
The Phase I Gene Therapy Study for Fabry Disease is looking to recruit interested patients. This is a first-in-human study for the treatment of Fabry disease.
The BALANCE study is a clinical research study that will compare the safety and efficacy of an investigational medication ( a potential new medication) with an approved medication, agalsidase beta, also known as Fabrazyme.